The Latest Breaking News from Vertex Pharmaceuticals

Vertex Pharmaceuticals got an upgrade Wednesday on its burgeoning non-cystic fibrosis pipeline — as VRTX stock inched higher.

Upgrades

The IBD SmartSelect Composite Rating for Vertex Pharmaceuticals increased from 94 to 96 Tuesday.

Over the past 3 months, 5 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

Vertex will need to lean on its pipeline to prop VRTX stock, an analyst said Thursday after the company delivered a mixed report.

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Vertex Pharmaceuticals's (NASDAQ:VRTX) short percent of float has risen 18.8% since its last report. The company recently reported that it has 4.01 million shares sold short, which is 1.58% of all regular shares that are available for trading.

Upgrades

The Dow Jones fell as the 10-year treasury yield spiked., A couple of Warren Buffett stocks popped higher. Intel led the blue chips.

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 6.39% on an annualized basis producing an average annual return of 17.51%. Currently, Vertex Pharmaceuticals has a market capitalization of $65.74 billion.